Fingerprint
Dive into the research topics of 'Pembrolizumab plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer with PDL1 Tumor Proportion Score ‡ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically